FIELD: medicine.
SUBSTANCE: claimed invention relates to the field of medications, particularly, to pharmaceutical tablet, including tablet base with distributed in it 0.1-10 mg of tamsulosin or its pharmaceutically acceptable salt, hydroxypropyl methyl cellulose in amount from 10 wt % to 90 wt %, and non-obligatory having enterosoluble coating over said base, where said tablet represents tablet with modified release. In addition, invention relates to method of treatment of benign prostate hyperplasia.
EFFECT: producing tamsulosin tablet with reduced dependence on food intake.
31 cl, 6 dwg, 12 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SITAGLIPTIN TANNATE COMPLEX | 2015 |
|
RU2696588C2 |
| TAMZULOSIN TABLETS | 2002 |
|
RU2311903C2 |
| SOLID DISPERSIONS | 2016 |
|
RU2694832C2 |
| PHARMACEUTICAL COMPOSITIONS OF ACOTIAMIDE AND PROTON PUMP INHIBITOR | 2019 |
|
RU2820820C2 |
| SOLID PER ORAL MEDICATION, CONTAINING INTENSIFIER | 2007 |
|
RU2437662C2 |
| DOSAGE FORM WITH IMPROVED CHARACTERISTICS OF pH-DEPENDENT RELEASE OF PREPARATION CONTAINING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2017 |
|
RU2716025C1 |
| METHOD OF OBTAINING ENTERIC COATED GRANULES CONTAINING PROTON PUMP INHIBITOR, AND PHARMACEUTICAL COMPOSITIONS, CONTAINING MULTIPLE PARTICLES AND SUCH GRANULES | 2015 |
|
RU2679652C1 |
| SOLID TABLETS AND CAPSULES OF MODIFIED RELEASE OF BENZONATATE | 2014 |
|
RU2673239C2 |
| TACROLIMUS FOR IMPROVED TREATMENT OF PATIENTS WITH GRAFTS | 2009 |
|
RU2574006C2 |
| DOSAGE FORMS OF RISEDRONATE | 2005 |
|
RU2381791C2 |
